Rheumatology International

, Volume 32, Issue 5, pp 1397–1401

Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1β signaling and a poor clinical response

  • Yasushi Matsuyama
  • Hitoaki Okazaki
  • Motoaki Hoshino
  • Sachiko Onishi
  • Yasuyuki Kamata
  • Katsuya Nagatani
  • Takao Nagashima
  • Masahiro Iwamoto
  • Taku Yoshio
  • Hiromi Ohto-Ozaki
  • Hiroyuki Tamemoto
  • Mayumi Komine
  • Hitoshi Sekiya
  • Shin-ichi Tominaga
  • Seiji Minota
Short Communication

DOI: 10.1007/s00296-011-1854-6

Cite this article as:
Matsuyama, Y., Okazaki, H., Hoshino, M. et al. Rheumatol Int (2012) 32: 1397. doi:10.1007/s00296-011-1854-6

Abstract

Although TNF inhibitors have dramatically improved the outcome of patients with rheumatoid arthritis, 30–40% of patients do not respond well to them and treatment needs to be changed. In an effort to discriminate good and poor responders, we focused on the change in serum and synovial fluid levels of interleukin (IL-) 33 before and after treatment with TNF inhibitors. They were also measured in synovial fluids from 17 TNF inhibitor-naïve patients, and fibroblast-like synoviocytes (FLS) in-culture from 6 patients and correlated with various pro-inflammatory cytokines. Serum levels of IL-33 at 6 months after treatment decreased significantly in responders, while they did not change in non-responders. Synovial fluid levels of IL-33 in 6 patients under treatment with TNF inhibitors stayed high in 3 who were refractory and slightly elevated in 2 moderate responders, while they were undetectable in one patient under remission. Among inflammatory cytokines measured in 17 synovial fluids from TNF inhibitor-naïve patients, levels of IL-33 showed a significant positive correlation only to those of IL-1β. IL-1β increased IL-33 expression markedly in FLS in vitro, compared to TNF-α. IL-1β might be inducing RA inflammation through producing pro-inflammatory IL-33 in TNF inhibitor-hypo-responders. Sustained elevation of serum and/or synovial levels of IL-33 may account for a poor response to TNF inhibitors, although how TNF inhibitors affect the level of IL-33 remains to be elucidated.

Keywords

Rheumatoid arthritis  Tumor necrosis factor TNF inhibitor Interleukin-33 ST2 Interleukin-1 family 

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Yasushi Matsuyama
    • 1
  • Hitoaki Okazaki
    • 1
  • Motoaki Hoshino
    • 1
  • Sachiko Onishi
    • 1
  • Yasuyuki Kamata
    • 1
  • Katsuya Nagatani
    • 1
  • Takao Nagashima
    • 1
  • Masahiro Iwamoto
    • 1
  • Taku Yoshio
    • 1
  • Hiromi Ohto-Ozaki
    • 2
  • Hiroyuki Tamemoto
    • 2
  • Mayumi Komine
    • 3
  • Hitoshi Sekiya
    • 4
  • Shin-ichi Tominaga
    • 2
  • Seiji Minota
    • 1
  1. 1.Division of Rheumatology and Clinical ImmunologyJichi Medical UniversityShimotsukeJapan
  2. 2.Department of BiochemistryJichi Medical UniversityShimotsukeJapan
  3. 3.Department of DermatologyJichi Medical UniversityShimotsukeJapan
  4. 4.Department of Orthopedic SurgeryJichi Medical UniversityShimotsukeJapan

Personalised recommendations